LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Начало・Списък с акции・Savara Inc

Savara Inc

Затворен

СекторЗдравеопазване

6.05 -0.17

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

5.9399999999999995

Максимум

6.15

Ключови измерители
By Trading Economics
Приходи	840K -30M
EPS	-0.14
Марж на печалбата	-10,677.941
Служители	59
EBITDA	841K -29M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+58.42% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	540M 1.3B
Предишно отваряне	6.22
Предишно затваряне	6.05

Настроения в новините

By Acuity

41%

59%

141 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

2.76 / 2.84 Подкрепа & съпротива

Savara Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.12.2025 г., 17:29 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19.12.2025 г., 16:47 ч. UTC

Значими двигатели на пазара

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19.12.2025 г., 16:10 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

19.12.2025 г., 22:33 ч. UTC

Печалби

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19.12.2025 г., 22:19 ч. UTC

Печалби

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19.12.2025 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19.12.2025 г., 21:44 ч. UTC

Печалби

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19.12.2025 г., 21:38 ч. UTC

Печалби

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19.12.2025 г., 21:00 ч. UTC

Пазарно говорене

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19.12.2025 г., 20:23 ч. UTC

Пазарно говорене

Oil Futures End Down Week on Up Note -- Market Talk

19.12.2025 г., 20:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19.12.2025 г., 18:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19.12.2025 г., 18:00 ч. UTC

Пазарно говорене

Печалби

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19.12.2025 г., 17:41 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19.12.2025 г., 17:24 ч. UTC

Пазарно говорене

Печалби

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

19.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

19.12.2025 г., 16:29 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19.12.2025 г., 16:20 ч. UTC

Придобивния, сливания и поглъщания

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19.12.2025 г., 16:19 ч. UTC

Придобивния, сливания и поглъщания

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19.12.2025 г., 16:18 ч. UTC

Придобивния, сливания и поглъщания

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19.12.2025 г., 16:16 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

19.12.2025 г., 16:16 ч. UTC

Пазарно говорене

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19.12.2025 г., 16:05 ч. UTC

Придобивния, сливания и поглъщания

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19.12.2025 г., 16:04 ч. UTC

Придобивния, сливания и поглъщания

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19.12.2025 г., 15:37 ч. UTC

Пазарно говорене

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19.12.2025 г., 15:21 ч. UTC

Пазарно говорене

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19.12.2025 г., 15:09 ч. UTC

Пазарно говорене

Gold Flat But Set for Weekly Gains -- Market Talk

19.12.2025 г., 15:09 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

19.12.2025 г., 15:09 ч. UTC

Печалби

FedEx Earnings Were Strong. The Stock Is Down. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Savara Inc Прогноза

Ценова цел

By TipRanks

58.42% нагоре

12-месечна прогноза

Среден 9.6 USD 58.42%

Висок 11 USD

Нисък 8 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Savara Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Savara Inc през последните 3 месеца.

Техническа оценка

By Trading Central

2.76 / 2.84Подкрепа & съпротива

The bullish and bearish events are balanced.

All events are bullish.

Bullish events outweigh bearish events.

Настроение

By Acuity

141 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Savara Inc

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.